Long-Term Real-World Outcomes of Corneal Changes in Proliferative Diabetic Retinopathy: Panretinal Photocoagulation vs. Intravitreal Conbercept

被引:0
|
作者
Li, Zijing [1 ,2 ]
Zhou, Lijun [1 ]
Huang, Chuangxin [1 ]
Lu, Tu [1 ]
Liang, Jiandong [1 ]
Cong, Qifeng [1 ]
Lan, Yuqing [2 ]
Jin, Chenjin [1 ,3 ]
机构
[1] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, 107 Yanjiang West Rd, Guangzhou 510020, Peoples R China
[3] 54 South Xianlie Rd, Guangzhou 510060, Peoples R China
关键词
Long-term; real-world; corneal thickness; anterior segment optical coherence; tomography; proliferative diabetic retinopathy; panretinal photocoagulation; conbercept; SENSATION; DENSITY;
D O I
10.1016/j.pdpdt.2023.103765
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare long-term real-world outcomes of corneal thickness (CT) alterations in proliferative diabetic retinopathy (PDR) patients treated with panretinal photocoagulation (PRP) and intravitreal conbercept (IVC). Methods: This retrospective study included 69 eyes of 69 patients with PDR (42 PRP and 27 IVC). Full corneal thickness (FCT), corneal epithelial thickness (CET) and corneal stromal thickness (CST) measured by anterior segment optical coherence tomography at baseline were compared between groups. These CT changes at last follow-up from baseline were also compared between groups and within each group. Results: During a mean follow-up of more than two years, the IVC group demonstrated a significantly increased corneal thickness from baseline compared to the PRP group in some areas (PRP vs. IVC: FCT 0-2 mm: -0.59 +/- 9.31 vs. 5.59 +/- 9.23 mu m, p = 0.009; CST 0-2 mm: -2.05 +/- 8.79 vs. 3.48 +/- 7.52 mu m, p = 0.015; CST 2-5 mm: -1.78 +/- 13.27 vs. 5.68 +/- 14.53 mu m, p = 0.046). In within-group comparisons, a significantly increased FCT from baseline was found in the 0-2 mm area in the IVC group (p = 0.004), but no significant change was observed in the PRP group (p = 0.691). For CET changes, a significantly increased CT was observed in the 0-2 mm, 2-5 mm and 5-7 mm areas in both groups respectively (all p < 0.05). Regarding CST, an increased CT was found in the 0-2 mm area in the IVC group (p = 0.037), while a decreased trend was observed in 0-2 mm and 2-5 mm areas in the PRP group (all p > 0.05). Conclusion: When using PRP or IVC in the long-term management of PDR, CT changes should be considered. This may provide evidence for corneal protection during PDR treatment.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Long-term longitudinal retinal changes after conventional and pattern scan laser panretinal photocoagulation in diabetic retinopathy
    Koca, Semra
    Kilic, Deniz
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2023, 44
  • [22] Long-term Changes in the Peripapillary RNFL and Macular GCIPL Thicknesses after Panretinal Photocoagulation in Diabetic Retinopathy Patients
    Yoon, Jung Hyun
    Park, Dong Ho
    Kim, Dai Woo
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2018, 59 (10): : 938 - 945
  • [23] Long-term outcomes of vitrectomy for proliferative diabetic retinopathy
    Schreur, V.
    Brouwers, J.
    van Huet, R. A. C.
    Smeets, S.
    Phan, M.
    Hoyng, C. B.
    de Jong, E. K.
    Klevering, B. J.
    ACTA OPHTHALMOLOGICA, 2020, 98 : 37 - 37
  • [24] Long-term outcomes of vitrectomy for proliferative diabetic retinopathy
    Schreur, Vivian
    Brouwers, Jody
    Van Huet, Ramon A. C.
    Smeets, Sandra
    Phan, Milan
    Hoyng, Carel B.
    deJong, Eiko K.
    Klevering, B. Jeroen
    ACTA OPHTHALMOLOGICA, 2021, 99 (01) : 83 - 89
  • [25] Outcomes of intravitreal anti-VEGF injections and panretinal photocoagulation in preretinal hemorrhage secondary to proliferative diabetic retinopathy involving the fovea
    Brar, Manpreet
    Sharma, Mansi
    Grewal, Satinder Pal Singh
    Dogra, Mangat
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (05) : 687 - 691
  • [26] Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy A Randomized Clinical Trial
    Gross, Jeffrey G.
    Glassman, Adam R.
    Liu, Danni
    Sun, Jennifer K.
    Antoszyk, Andrew N.
    Baker, Carl W.
    Bressler, Neil M.
    Elman, Michael J.
    Ferris, Frederick L.
    Gardner, Thomas W.
    Jampol, Lee M.
    Martin, Daniel F.
    Melia, Michele
    Stockdale, Cynthia R.
    Beck, Roy W.
    JAMA OPHTHALMOLOGY, 2018, 136 (10) : 1138 - 1148
  • [27] Patient Comfort with Yellow (577 nm) vs. Green (532 nm) Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
    Adam, Murtaza K.
    Weinstock, Brett M.
    Kasi, Sundeep K.
    Ehmann, David S.
    Hsu, Jason
    Garg, Sunir J.
    Ho, Allen C.
    Chiang, Allen
    OPHTHALMOLOGY RETINA, 2018, 2 (02): : 91 - 95
  • [28] Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
    Johanna J. Zirpel
    Isabel B. Pfister
    Christin Gerhardt
    Justus G. Garweg
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 3569 - 3578
  • [29] Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
    Zirpel, Johanna J.
    Pfister, Isabel B.
    Gerhardt, Christin
    Garweg, Justus G.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (12) : 3569 - 3578
  • [30] Retinal vein changes in patients with high-risk proliferative diabetic retinopathy treated with conbercept and panretinal photocoagulation co-therapy: a cohort study
    Si, Mingwei
    Tao, Yuan
    Zhang, Ziniu
    Zhao, Hui
    Cui, Wenxuan
    Yang, Mengyao
    Wang, Hong
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14